ImmunoBrain presented Phase 1b results for IBC-Ab002, its anti-PD-L1 immune checkpoint therapy, at AD/PD 2026 in Copenhagen. The randomized, double-blind, placebo-controlled IBC-01-01 trial enrolled 40 patients with early Alzheimer’s across sites in the U.K., the Netherlands and Israel and evaluated safety, tolerability and pharmacokinetics as primary and secondary endpoints, with exploratory cerebrospinal fluid biomarker measures at 12 months.
According to the company, immune-related adverse events were generally mild and manageable, with no serious adverse events related to the study drug and no cases of amyloid-related imaging abnormalities. At a 30 mg/kg dose, changes in CSF neurogranin, total-Tau and pTau181 versus placebo were described as directionally favorable and concordant with potential synaptic and neuronal protection.
The company claims IBC-Ab002 is engineered for intermittent PD-1/PD-L1 blockade to reinvigorate adaptive immunity while limiting chronic exposure. ImmunoBrain is designing the next clinical phase to include cognitive endpoints; the company noted the data are preliminary and the trial was supported in part by the National Institute on Aging (NIA) and the Alzheimer’s Association.
